1 TOLLYS SAS, 60F avenue Rockefeller, Lyon, France; Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

2 Service d’Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France. Université Claude Bernard Lyon 1; TOLLYS SAS, 60F avenue Rockefeller, Lyon, France; Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

3 Service d’Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France; Univ Lyon, Université Claude Bernard Lyon 1.

Keywords: Toll-like receptor 3, agonist, cancer therapy, apoptosis, inflammation.

Abbreviations:

dsRNA – double-stranded RNA,

HMW – high molecular weight,

hIL – human interleukin,

KO – knockout,

LPS – lipopolysaccharide,

mTNFα – murine TNFα,

PMo – primary monocytes,

TLR – Toll-like receptor,

wt – wild type.
Received originally: 30/11/2022 Received in revised form: 22/03/2023
Accepted: 12/04/2023 Published: 19/04/2023

Correspondence:
Marc Bonnin, PhD, TOLLYS SAS, 60F avenue Rockefeller, Lyon, France; Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France; mbonnin@tollys.fr; marc_bonnin@hotmail.com

Conflict of interest statement: ST, SM, AB, LD, CP, NV, SO, MS, SC, MBJ, BW, and MB are employees of TOLLYS SAS company (Lyon, France). A patent was filled in 2019 (Bonnin M. & Thierry S., WO2019/211492 A1, “TLR3 LIGANDS THAT ACTIVATE BOTH EPITHELIAL AND MYELOID CELLS”).
Please cite this article as: Sylvain Thierry, Sarah Maadadi, Aurore Berton, Laura Dimier, Clémence Perret, Nelly Vey, Saïd Our-fali, Mathilde Saccas, Solène Caron, Mathilde Boucard-Jourdin, Marc Colombel, Bettina Werle and Marc Bonnin (2023). TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting can-cers: discovery process and biological characterization. Microbial Cell 10(5): 117-132. doi: 10.15698/mic2023.06.797